{"title":"Nonhuman Primate Models for HIV/AIDS Vaccine Development","authors":"Yongjun Sui, Shari Gordon, Genoveffa Franchini, Jay A. Berzofsky","doi":"10.1002/0471142735.im1214s102","DOIUrl":null,"url":null,"abstract":"<p>The development of HIV vaccines has been hampered by the lack of an animal model that can accurately predict vaccine efficacy. Chimpanzees can be infected with HIV-1 but are not practical for research. However, several species of macaques are susceptible to the simian immunodeficiency viruses (SIVs) that cause disease in macaques, which also closely mimic HIV in humans. Thus, macaque-SIV models of HIV infection have become a critical foundation for AIDS vaccine development. Here we examine the multiple variables and considerations that must be taken into account in order to use this nonhuman primate (NHP) model effectively. These include the species and subspecies of macaques, virus strain, dose and route of administration, and macaque genetics, including the major histocompatibility complex molecules that affect immune responses, and other virus restriction factors. We illustrate how these NHP models can be used to carry out studies of immune responses in mucosal and other tissues that could not easily be performed on human volunteers. Furthermore, macaques are an ideal model system to optimize adjuvants, test vaccine platforms, and identify correlates of protection that can advance the HIV vaccine field. We also illustrate techniques used to identify different macaque lymphocyte populations and review some poxvirus vaccine candidates that are in various stages of clinical trials. Understanding how to effectively use this valuable model will greatly increase the likelihood of finding a successful vaccine for HIV. <i>Curr. Protoc. Immunol</i>. 102:12.14.1-12.14.30. © 2013 by John Wiley & Sons, Inc.</p>","PeriodicalId":10733,"journal":{"name":"Current Protocols in Immunology","volume":"102 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/0471142735.im1214s102","citationCount":"48","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Immunology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/0471142735.im1214s102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
引用次数: 48
Abstract
The development of HIV vaccines has been hampered by the lack of an animal model that can accurately predict vaccine efficacy. Chimpanzees can be infected with HIV-1 but are not practical for research. However, several species of macaques are susceptible to the simian immunodeficiency viruses (SIVs) that cause disease in macaques, which also closely mimic HIV in humans. Thus, macaque-SIV models of HIV infection have become a critical foundation for AIDS vaccine development. Here we examine the multiple variables and considerations that must be taken into account in order to use this nonhuman primate (NHP) model effectively. These include the species and subspecies of macaques, virus strain, dose and route of administration, and macaque genetics, including the major histocompatibility complex molecules that affect immune responses, and other virus restriction factors. We illustrate how these NHP models can be used to carry out studies of immune responses in mucosal and other tissues that could not easily be performed on human volunteers. Furthermore, macaques are an ideal model system to optimize adjuvants, test vaccine platforms, and identify correlates of protection that can advance the HIV vaccine field. We also illustrate techniques used to identify different macaque lymphocyte populations and review some poxvirus vaccine candidates that are in various stages of clinical trials. Understanding how to effectively use this valuable model will greatly increase the likelihood of finding a successful vaccine for HIV. Curr. Protoc. Immunol. 102:12.14.1-12.14.30. © 2013 by John Wiley & Sons, Inc.
艾滋病毒/艾滋病疫苗开发的非人灵长类动物模型
由于缺乏能够准确预测疫苗效力的动物模型,艾滋病毒疫苗的开发受到了阻碍。黑猩猩可以感染HIV-1,但不适用于研究。然而,一些种类的猕猴容易感染猴免疫缺陷病毒(SIVs),这种病毒在猕猴中引起疾病,也非常类似于人类的艾滋病毒。因此,猕猴siv模型已成为艾滋病疫苗开发的重要基础。在这里,我们检查了为了有效地使用这种非人类灵长类动物(NHP)模型必须考虑的多个变量和考虑因素。这些因素包括猕猴的种类和亚种、病毒株、剂量和给药途径,以及猕猴遗传学,包括影响免疫反应的主要组织相容性复合体分子,以及其他病毒限制因素。我们说明了这些NHP模型如何用于研究粘膜和其他组织中的免疫反应,而这些研究不容易在人类志愿者身上进行。此外,猕猴是一个理想的模型系统,可以优化佐剂,测试疫苗平台,并确定可以推进HIV疫苗领域的保护相关因素。我们还说明了用于识别不同猕猴淋巴细胞群的技术,并回顾了一些处于不同临床试验阶段的痘病毒候选疫苗。了解如何有效地利用这一有价值的模型将大大增加找到成功的艾滋病毒疫苗的可能性。咕咕叫。Protoc。Immunol 102:12.14.1-12.14.30。©2013 by John Wiley &儿子,Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。